Therapie mit Thrombozyten

  • H. Kroll
  • V. Kiefel
Chapter

Zusammenfassung

Blutplättchen sind die zellulären Elemente des Hämostasesystems. Sie tragen zur Aufrechterhaltung der Gefäßwandintegrität bei und sorgen nach Verletzung für die Bildung eines hämostatisch wirksamen Pfropfes. Auf ihrer Oberfläche laufen wesentliche Prozesse der plasmatischen Gerinnung ab. Die medizinische Bedeutung der Therapie mit Thrombozyten kommt heutzutage der von Erythrozytenkonzentraten nahe. In Deutschland werden derzeit mehr als 400.000 Thrombozytentransfusionen jährlich durchgeführt. Während in den meisten Fällen eine effiziente Versorgung mit geeigneten Thrombozytenpräparaten möglich ist, kann ein immunologischer Refraktärzustand erhebliche Schwierigkeiten bei der Behandlung einzelner Patienten verursachen.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.
    Andreu G, Dewailly J (1994) Prevention of HLA alloimmunization by using leukocyte-depleted components. Curr Stud Hem Blood Transfus 60:29–40Google Scholar
  2. 2.
    Anonymous, Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components (2001) Pathogen inactivation of labile blood products. Transfus Med 11:149–175CrossRefGoogle Scholar
  3. 3.
    Aster RH (1966) Pooling of platelets in the spleen: role in the pathogenesis of »hypersplenic« thrombocytopenia. J Clin Invest 45:645–657PubMedCrossRefGoogle Scholar
  4. 4.
    Atoyebi W, Mundy N, Croxton T, Littlewood TJ, Murphy MF (2000) Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? Br J Haematol 111:980–983PubMedCrossRefGoogle Scholar
  5. 5.
    Baer MR, Bloomfield CD (1992) Prophylactic platelet transfusion therapy: Pro. Transfusion 32:377–380PubMedCrossRefGoogle Scholar
  6. 6.
    Benson K, Marks AR, Marshall MJ, Goldstein JD (1994) Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLAhomozygous platelets from unrelated donors. Transfusion 34:432–437PubMedCrossRefGoogle Scholar
  7. 7.
    Beutler E (1993) Artificial preservatives for platelets. Transfusion 33:279–280PubMedCrossRefGoogle Scholar
  8. 8.
    Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J (1991) Factors influencing 20-hour increments after platelet transfusion. Transfusion 31:392–396PubMedCrossRefGoogle Scholar
  9. 9.
    Bishop JF, Matthews JP, Yuen K, McGrath K, Wolf MM, Szer J (1992) The definition of refractoriness to platelet transfusions. Transfus Med 2:35–41PubMedCrossRefGoogle Scholar
  10. 10.
    Blajchman MA, Goldman M (2001) Bacterial contamination of platelet concentrates: incidence, significance and prevention. Sem Hema 4 Suppl 11:20–26CrossRefGoogle Scholar
  11. 11.
    Blumberg N, Heal JM, Hicks GL, Risher WH (2001) Association of ABOmismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 41:790–793PubMedCrossRefGoogle Scholar
  12. 12.
    Böck M, Rahrig S, Kunz D, Lutze G, Heim MU (2002) Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfus Med 12:311–316CrossRefGoogle Scholar
  13. 13.
    Brand A (1994) Passenger leukocytes, cytokines and transfusion reactions. N Engl J Med 331:670–671PubMedCrossRefGoogle Scholar
  14. 14.
    Brand A (2001) Alloimmune platelet refractoriness: incidence declines, unsolved problems persist. Transfusion 41:724–726PubMedCrossRefGoogle Scholar
  15. 15.
    Branehög I, Kutti J, Weinfeld A (1974) Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 27:127–143PubMedCrossRefGoogle Scholar
  16. 16.
    Callow CR, Swindell R, Randall W, Chopra R (2002) The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol 118:677–682PubMedCrossRefGoogle Scholar
  17. 17.
    Couban S, Carruthers J, Andreou P, et al. (2002) Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion 42:753–758PubMedCrossRefGoogle Scholar
  18. 18.
    Davis KB, Slichter SJ, Corash L (1999) Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 39:586–592PubMedCrossRefGoogle Scholar
  19. 19.
    Delaflor-Weiss E, Mintz PD (2000) The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 14:180–196PubMedCrossRefGoogle Scholar
  20. 20.
    de la Rubia J, Plume G, Arriaga F, et al. (2002) Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion 42:1384–1385PubMedCrossRefGoogle Scholar
  21. 21.
    de Wildt-Eggen J, Nauta S, Schrijver JG, et al. (2000) Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 40:398–403PubMedCrossRefGoogle Scholar
  22. 22.
    Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister TA, Waters AH (1994) Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 66:200–205PubMedCrossRefGoogle Scholar
  23. 23.
    Duke WW (1910) The relation of blood platelets to hemorrhagic disease: description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA 55:1185–1192CrossRefGoogle Scholar
  24. 24.
    Dumont LJ, AuBuchon JP, Whitley P, et al. (2002) Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 42:847–854PubMedCrossRefGoogle Scholar
  25. 25.
    Ferrara JLM (1995) The febrile platelet transfusion reaction: a cytokine shower. Transfusion 35:89–90PubMedCrossRefGoogle Scholar
  26. 26.
    Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S (2002) Do basic laboratory tests or clinical observations predict bleeding in thromobcytopenic patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 16:34–45PubMedCrossRefGoogle Scholar
  27. 27.
    Gawaz M (1999) Das Blutplättchen. Thieme, Stuttgart New YorkGoogle Scholar
  28. 28.
    Gharpure VS, Norris D, Lee EJ, Schiffer CA (1994) Use of »split« plateletpheresis products for alloimmunized patients. Vox Sang 67:272–274PubMedCrossRefGoogle Scholar
  29. 29.
    Gmür J, Burger J, Schanz U, Fehr J, Schaffner A (1991) Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 338:1223–1226PubMedCrossRefGoogle Scholar
  30. 30.
    Greinacher A, Kiefel V, Klüter H, Kroll H, Pötzsch B, Riess H (2006) Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfus Med Hemother 33:528–543CrossRefGoogle Scholar
  31. 31.
    Grishaber JE, Birney SM, Strauss RG (1993) Potential for transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA class I antigens. Transfusion 33:910–914PubMedCrossRefGoogle Scholar
  32. 32.
    Hanson SR, Slichter SJ (1985) Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 66:1105–1109PubMedGoogle Scholar
  33. 33.
    Harkness DR, Byrnes JJ, Lian EC, Williams WD, Hensley GT (1981) Hazard of platelet transfusion in thrombotic thrombocytopenic pupura. JAMA 246:1931–1933PubMedCrossRefGoogle Scholar
  34. 34.
    Harrison P, Robinson M, Liesner R, et al. (2002) The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haem 24:225–232CrossRefGoogle Scholar
  35. 35.
    Heddle NM, Blajchman MA (1995) The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 85:603–606PubMedGoogle Scholar
  36. 36.
    Heddle NM, Klama L, Singer J, et al. (1994) The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 331:625–628PubMedCrossRefGoogle Scholar
  37. 37.
    Heddle NM, Soutar RL, O’Hoski PL, Singer J, McBride JA, Ali MAM, Kelton JG (1995) A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 91:1000–1005PubMedCrossRefGoogle Scholar
  38. 38.
    Heddle NM, Blajchman MA, Meyer RM, et al. (2002) A randomized, controlled trial comparing the frequency of acute reactions to plasmaremoved platelets and prestorage WBC-reduced platelets. Transfusion 42:556–566PubMedCrossRefGoogle Scholar
  39. 39.
    Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ (2008) Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 48:1447– 1458PubMedCrossRefGoogle Scholar
  40. 40.
    Heim MU, Böck M, Kolb H-J, Schleuning M, Mempel W (1992) Intravenous anti-D gammaglobulin for the prevention of Rhesus isoimmunization caused by platelet transfusions in patients with malignant diseases. Vox Sang 62:165–168PubMedCrossRefGoogle Scholar
  41. 41.
    Hopkins CK, Goldfinger D (2008) Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion 48:2128–2132PubMedCrossRefGoogle Scholar
  42. 42.
    Kantarjian H, Fenaux P, Sekeres MA, et al. (2010) Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 28:437-444PubMedCrossRefGoogle Scholar
  43. 43.
    Kickler T, Braine HG, Piantadosi S, et al. (1990) A randomized, placebocontrolled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 75:313–316PubMedGoogle Scholar
  44. 44.
    Kiefel V, König C, Kroll H, Santoso S (2001) Platelet alloantibodies in transfused patients. Transfusion 41:766–770PubMedCrossRefGoogle Scholar
  45. 45.
    Klüter H, Salama A (2001) Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten: Thrombozytenkonzentrate. Deutscher Ärzteverlag, Köln, S 27–43Google Scholar
  46. 46.
    Kretschmer V, Huss B, Weber S, Bewarder S, Schulzki T, Köppler H, Heimanns J (1994) A contribution to the indications for platelet transfusion and determination of its therapeutic efficacy. Transfus Sci 15:361–369PubMedCrossRefGoogle Scholar
  47. 47.
    Kuter DJ, Goodnough LT, Romo J, et al. (2001) Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 98:1339–1345PubMedCrossRefGoogle Scholar
  48. 48.
    Li J, Yang Ch, Xia Y, et al. (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241–3248PubMedCrossRefGoogle Scholar
  49. 49.
    Lonzano M, Cid J (2003) The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 17:57–68CrossRefGoogle Scholar
  50. 50.
    Moog R (2009) Feasibility and safety of triple dose platelet collection by apheresis. J Clin Apher 24:238-240PubMedCrossRefGoogle Scholar
  51. 51.
    Moroff G, Garratty G, Heal JM, MacPherson BR, Stroncek D, Huang ST, Ho W, Petz LD, Leach MF, Lennon SS, Rowe JM, Saleh MN, Arndt P, Foley K, Masel D, Postoway N (1992) Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 32:633–640PubMedCrossRefGoogle Scholar
  52. 52.
    Murphy MF, Brozovic B, Murphy W, Ouwehand W, Waters AH (1992) Guidelines for platelet transfusions. Transfus Med 2:311–318PubMedCrossRefGoogle Scholar
  53. 53.
    Murphy S (2002) What’s so bad about old platelets? Transfusion 42:809–811PubMedCrossRefGoogle Scholar
  54. 54.
    Muylle L, Wouters E, de Bock R, Peetermans ME (1992) Reactions to platelet transfusion: the effect of the storage time of the concentrate. Transfus Med 2:289–293PubMedCrossRefGoogle Scholar
  55. 55.
    Nambiar A, Duquesnoy RJ, Adams S, et al. (2006) HLAMatchmakerdriven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 107:1680–1687PubMedCrossRefGoogle Scholar
  56. 56.
    Ness PM, Campbell-Lee SA (2001) Single donor versus random donor platelet concentrates. Curr Opin Hem 8:392–396CrossRefGoogle Scholar
  57. 57.
    Ness PM, Braine H, King K, Barrasso C, Kickler T, Fuller A, Blades N (2001) Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 41:857–861PubMedCrossRefGoogle Scholar
  58. 58.
    Novotny VMJ, van Doorn R, Witvliet MD, Claas FHJ, Brand A (1995) Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 85:1736–1741PubMedGoogle Scholar
  59. 59.
    Panzer S, Kiefel V, Bartram CR, Haas OA, Hinterberger W, Mueller-Eckhardt C, Lechner K (1989) Immune thrombocytopenia more than a year after allogenetic marrow transplantation due to antibodies against donor platelets with anti-Pl(A1) specificity: evidence for a host-derived immune reaction. Br J Haematol 71:259–264PubMedCrossRefGoogle Scholar
  60. 60.
    Patten E (1992) Prophylactic platelet transfusion revisited after 25 years: con. Transfusion 32:381–385PubMedCrossRefGoogle Scholar
  61. 61.
    Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten (2009) Deutscher Ärzteverlag, KölnGoogle Scholar
  62. 62.
    Rebulla P, Finazzi G, Marangoni F, et al. (1997) The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. New England Journal of Medicine 337:1870–1875PubMedCrossRefGoogle Scholar
  63. 63.
    Reesink HW, Nydegger UE, Brand A, et al. (1992) International Forum: Should all platelet concentrates issued be lookocyte-poor? Vox Sang 62:60–61CrossRefGoogle Scholar
  64. 64.
    Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) Gesamtnovelle 2005. Deutscher Ärzteverlag, KölnGoogle Scholar
  65. 65.
    Rock GA (1993) The application of protein A immunoadsorption to remove platelet alloantibodies. Transfusion 33:192–194PubMedCrossRefGoogle Scholar
  66. 66.
    Rock GA (2000) Management of thrombotic thrombocytopenic purpura. Br J Haematol 109:496–507PubMedCrossRefGoogle Scholar
  67. 67.
    Saarinen UM, Koskimies S, Myllylä G (1993) Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer. Vox Sang 65:286–292PubMedCrossRefGoogle Scholar
  68. 68.
    Sagmeister M, Oec L, Gmür J (1999) A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 93:3124–3126PubMedGoogle Scholar
  69. 69.
    Sanz C, Freire C, Alcorta I, Ordinas A, Pereira A (2001) Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 41:762–765PubMedCrossRefGoogle Scholar
  70. 70.
    Schiffer CA (2001) Diagnosis and management of refractoriness to platelet transfusion. Blood Reviews 15:175–180PubMedCrossRefGoogle Scholar
  71. 71.
    Schiffer CA, Anderson KC, Bennett CL, et al. (2001) Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519–1538PubMedGoogle Scholar
  72. 72.
    Schnaidt M, Northoff H, Wernet D (1996) Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 6:111–114PubMedCrossRefGoogle Scholar
  73. 73.
    Schrezenmeier H, Seifried E (2010) Buffy-coat derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 99:1–15PubMedCrossRefGoogle Scholar
  74. 74.
    Schrezenmeier H, Walther-Wenke G, Müller TH, et al. (2007) Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 47:644–652PubMedCrossRefGoogle Scholar
  75. 75.
    Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K (2009) ABOidentical versus nonidentical platelet transfusions: a systematic review. Transfusion 49:2442–2453PubMedCrossRefGoogle Scholar
  76. 76.
    Shivdasani RA, Anderson KC (1993) Transfusion-associated graft-versus-host disease: scratching the surface. Transfusion 33:696–697PubMedCrossRefGoogle Scholar
  77. 77.
    Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Putten WLJ, Claas FHJ, Novotny VMJ, Brand A (1995) Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 85:824–828PubMedGoogle Scholar
  78. 78.
    Skogen B, Rossebo’ Hansen B, Husebekk A, Havnes T, Hannestad K (1988) Minimal expression of blood group A antigen on thrombocytes from A2 individuals. Transfusion 28:456–459PubMedCrossRefGoogle Scholar
  79. 79.
    Slichter SJ (1990) Mechanisms and Management of Platelet Refractoriness. In: Nance SJ (ed) Transfusion Medicine in the 1990’s. American Association of Blood Banks, Arlington, pp 95–179Google Scholar
  80. 80.
    Slichter SJ (2004) Relationship between platelet count and bleeding risr in thrombocytopenic patients. Transfus Med Rev 18:153–167PubMedCrossRefGoogle Scholar
  81. 81.
    Slichter SJ, Kaufman RM, Assmann SF, et al. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. 362:600–613Google Scholar
  82. 82.
    Söhngen D, Hattstein E, Heyll A, Kuntz BME, Meckenstock G, Schneider W (1994) Ex-vivo-Blutungszeit zur Kontrolle der Thrombozytentransfusion. Beiträge zur Infusionstherapie und Transfusionsmedizin 32:459–466PubMedGoogle Scholar
  83. 83.
    Stefanini M, Dameshek W (1953) Collection, preservation and transfusion of platelets. N Engl J Med 248:797–802PubMedCrossRefGoogle Scholar
  84. 84.
    Taaning E, Jacobsen N, Morling N (1994) Graft-derived anti-HPA-2 b production after allogeneic bone-marrow transplantation. Br J Haematol 86:651–653PubMedCrossRefGoogle Scholar
  85. 85.
    The Panel on Diagnostic Application of Radioisotopes in Hematology, International Committe for Standardization in Hematology (1977) Recommended methods for radioisotope platelet survival studies. Blood 50:1137–1144Google Scholar
  86. 86.
    The Trial to Reduce Alloimmunization to Platelets Study Group (1997) Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337:1861–1869CrossRefGoogle Scholar
  87. 87.
    van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman J-WN (1991) Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood 77:201–205PubMedGoogle Scholar
  88. 88.
    Wandt H, Frank M, Ehninger G, et al. (1998) Safety and cost-effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91:3601–3606PubMedGoogle Scholar
  89. 89.
    Wernet D, Northoff H, Schnaidt M (1994) Reactivation of antibodies of donor and recipient origin to platelet antigens early after allogeneic bone marrow transplantation: a case report. Br J Haematol 88:615–617PubMedCrossRefGoogle Scholar
  90. 90.
    Yankee RA, Grumet FC, Rogentine GN (1969) Platelet transfusion therapy. N Engl J Med 281:1208–1212PubMedCrossRefGoogle Scholar
  91. 91.
    Zumberg MS, del Rosario ML, Nejame CF, et al. (2002) A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10 000/L versus 20 000/L trigger. Biol Blood Marrow Transplant 8:569–576PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • H. Kroll
    • 1
  • V. Kiefel
    • 2
  1. 1.Institut für Transfusionsmedizin Dessau DRK-Blutspendedienst NSTOBDessau
  2. 2.Abteilung für TransfusionsmedizinUniversitätsklinikum Rostock AöRRostock

Personalised recommendations